View clinical trials related to Multiple Sclerosis.
Filter by:To study the success of Oligodendrocyte progenitor cell culture project in Rajavithi Hospital to identify an unlimited clone human neuronal progenitor stem cells from the human brain in the Biomolecular Research Center. This study aims to produce the reproductive clone of neuronal development protocols and advance projects. Neuronal cells such as pyramidal cells, oligodendrocyte, and dopaminergic neuron differentiation protocol/projects for treatment of Alzheimer's disease, Multiple sclerosis, and Parkinson's disease respectively in next phase of clinical trials.
The purpose of this study is to look at multiple sclerosis patients process of awareness, learning, and judging status over a 3 year time period.
The investigators' overall hypothesis is that appearance or worsening of relapsing-remitting multiple sclerosis (RR-MS) symptoms are affected by various factors including stress, hormonal cycles, illness and missed medications.
This study is designed to evaluate the neuroprotective effect of lamotrigine in the combination of interferon beta 1a once weekly intramuscular in patients with relapsing-remitting multiple sclerosis.
Determine patient satisfaction with the single-use autoinjector for the delivery of pre-filled Avonex syringe.
To collect data on serious adverse events which occur during extended treatment with Avonex in subjects at high risk for developing multiple sclerosis (MS) and in subjects with secondary progressive MS.
People with multiple sclerosis (MS) often experience problems with cognitive functioning, which can be debilitating and interfere with their daily functioning. However, research has shown that MS disease modifying agents have had some success in treating cognitive problems. The main purpose of this research study is to investigate how well two medicines (alemtuzumab (Campath®) and interferon beta-1a (Rebif®)) work in treating MS-related cognitive problems (e.g., attention, memory, speed of thinking). Participants enrolled will be assessed prior to their first study-related medication dose and re-assessed throughout treatment. It is expected that participants taking Campath® will demonstrate relative stability in cognitive functioning relative to those taking Rebif®. Specifically, the cognitive performance of Rebif® participants will decline somewhat over time, but the cognitive performance of Campath® participants will remain stable.
To explore the safety and efficacy of IPX056 compared with baclofen tablets for alleviation of symptoms of spasticity associated with multiple sclerosis (MS).
This study will look at differences in bioanalytical measures among different groups of MS patients and Healthy Volunteers, when administered interferon beta-1a.
The aims of this prospective, randomized study are: - To assess the effect of clean intermittent catheterization (CIC) - To investigate if MS patients will have symptom reduction (urgency, frequency, nocturia and incontinence) when using CIC in combination with anticholinergic drugs - To identify at what volume of Postvoid Residual (PVR) urine, starting CIC improves bladder control and QoL - To increase the evidence of CIC, and support clinical guidelines of bladder management in MS patients